ROWAN: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial ToEvaluate The Efficacy and Safety Of TheraSphere followed by Durvalumab (Imfinzi?) WithTremelimumab, Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)

Project: Research project

Project Details

Description

ROWAN: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere followed by Durvalumab (Imfinzi?) With Tremelimumab, Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)
StatusActive
Effective start/end date7/1/226/30/26

Funding

  • Boston Scientific Corporation

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.